Hymovis® Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis:

Exclusion Criteria

• •Presence, on clinical evaluation, of adhesive capsulitis
• •Evidence of rotator cuff injury
• •Presence of primary extra-articular shoulder syndromes (eg impingement, bursitis, tendonitis)
• •Evidence of clinically significant shoulder deformity
• •Signs, evident on X-ray radiography of the shoulder, of recent fractures, severe loss of bone density and/or severe deformity
• •Diagnosed with crystal deposition disease of calcium pyrophosphate dihydrate (CPPD) or chondrocalcinosis of the shoulder
• •Presence of pathology of the cervical vertebrae (able to alter the clinical evaluation) which, in the three months preceding the inclusion visit, was symptomatic and required active treatment
• •Presence of any active musculoskeletal disease affecting the diagnosis/evaluation of shoulder pain or presence of pain of any neurological etiology and acute shoulder infection
• •Presence of major surgery, arthroplasty or arthroscopy in the shoulder under study in the 6 months prior to inclusion and/or surgery planned during the study
• •Patient undergoing local radiotherapy for breast cancer
• •Patient with polymyalgia rheumatica
• •History of skin cancer (except basal cell carcinoma) treated for less than two years
• •History of severe recurrent or immune-mediated allergic reactions
• •Presence of infection and/or skin pathologies in the injection area; psoriasis
• •Presence of serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular, neurological disorders that could interfere with the study results or patient's inability to comply with the study requirements
• •Known allergy or suspected allergic reactions to hyaluronate or corticosteroid preparations
• •Taking HA products intra-articularly in the month preceding the inclusion visit
• •Taking bisphosphonates and/or pharmaceutical products taken orally and containing glucosamine and/or chondroitin sulphate and/or diacerin (eg Chondrosulf, Structum 500, Dona, Viatril, Fisiodar, Artrodar, etc.) in the month preceding the inclusion visit unless the dosage was stable in the two months prior to the inclusion visit
• •Intra-articular corticosteroid injections in the study shoulder in the three months preceding the inclusion visit
• •Intra-articular corticosteroid injections in any joint in the month preceding the inclusion
• •Taking oral corticosteroids in the month prior to the inclusion visit (only inhaled corticosteroids are permitted)
• •Previous use of HA in the study shoulder within 6 months prior to inclusion
• •Changed physical therapy in the month prior to inclusion visit or unwillingness to maintain stable regimen
• •Patient with history of thyroid insufficiency
• •Patient being treated with anticoagulant therapy
• •Patient on phenobarbital treatment prior to study inclusion
• •Taking analgesic therapies (NSAIDs, opioid analgesics, topical analgesics) for any condition that could interfere with the evaluation of the shoulder under study
• •Intake of another experimental product in the month preceding the inclusion visit
• •Patient who, in the opinion of the investigator, is unwilling to comply with study procedures or will not cooperate during the course of the study
• •Pregnant or breastfeeding woman